GlassScriptPhysician profile
Sarah Skillman
NPI 1801157615
$1,960.43
in general payments reported to CMS, 2019-2025
18 companies · $530 in 2025
The $530 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2021: $129 · 2022: $125 · 2023: $469 · 2024: $380 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.26 |
| Education | $132.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $625.45 | 2019-2025 | Dupixent |
| Genzyme Corporation | $299.28 | 2021-2025 | |
| Janssen Biotech, INC. | $181.52 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $145.52 | 2022-2024 | |
| Lilly USA, LLC | $108.10 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $101.62 | 2019-2023 | Arazlo, Duobrii, Jublia |
| Amgen INC. | $97.75 | 2022-2025 | Otezla, Otezla, Enbrel |
| Abbvie INC. | $90.14 | 2022-2024 | Rinvoq |
| Sun Pharmaceutical Industries INC. | $74.65 | 2025 | |
| Incyte Corporation | $48.08 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $43.36 | 2023 | Adbry |
| Ucb, INC. | $29.86 | 2024 | Bimzelx |
| Organon LLC | $25.87 | 2025 | Vtama |
| Dermavant Sciences, INC. | $20.68 | 2024 | Vtama |
| Pierre Fabre Pharmaceuticals, INC. | $18.96 | 2025 | Hemangeol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $18.90 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $18.80 | 2024 | Zoryve |
| Pfizer INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Skillman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.